- JTE-013
-
- $70.00 / 5mg
-
2026-01-09
- CAS:383150-41-2
- Min. Order:
- Purity: 99.65%
- Supply Ability: 10g
|
| | JTE-013 Basic information |
| Product Name: | JTE-013 | | Synonyms: | 1-[1,3-Dimethyl-4-(2-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-(2,6-dichloro-4-pyridinyl)-semicarbazide;1-(2,6-dichloro-4-pyridyl)-3-[(4-isopropyl-1,3-dimethyl-pyrazolo[3,4-b]pyridin-6-yl)amino]urea;1-[1,3-Dimethyl-4-(2-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]-4-(3,5-dichloro-4-pyridinyl)-semicarbazide;CS-2553;N-(2,6-Dichloro-4-pyridinyl)-2-[1,3-dimethyl-4-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]hydrazinecarboxamide;JTE-013;JTE 013;JTE013;1-(2,6-dichloropyridin-4-yl)-3-[(1,3-dimethyl-4-propan-2-ylpyrazolo[3,4-b]pyridin-6-yl)amino]urea;Hydrazinecarboxamide, N-(2,6-dichloro-4-pyridinyl)-2-[1,3-dimethyl-4-(1-methylethyl)-1H-pyrazolo[3,4-b]pyridin-6-yl]- | | CAS: | 383150-41-2 | | MF: | C17H19Cl2N7O | | MW: | 408.29 | | EINECS: | | | Product Categories: | | | Mol File: | 383150-41-2.mol |  |
| | JTE-013 Chemical Properties |
| density | 1.50±0.1 g/cm3(Predicted) | | storage temp. | 2-8°C | | solubility | DMSO: ≥20mg/mL | | pka | 9.32±0.43(Predicted) | | form | powder | | color | white to off-white | | InChI | 1S/C17H19Cl2N7O/c1-8(2)11-7-14(22-16-15(11)9(3)25-26(16)4)23-24-17(27)20-10-5-12(18)21-13(19)6-10/h5-8H,1-4H3,(H,22,23)(H2,20,21,24,27) | | InChIKey | RNSLRQNDXRSASX-UHFFFAOYSA-N | | SMILES | Clc1nc(cc(c1)NC(=O)NNc2nc3[n](nc(c3c(c2)C(C)C)C)C)Cl |
| Hazard Codes | T | | Risk Statements | 25 | | Safety Statements | 45 | | RIDADR | UN 2811 6.1 / PGIII | | WGK Germany | 3 | | Storage Class | 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | | Hazard Classifications | Acute Tox. 3 Oral |
| | JTE-013 Usage And Synthesis |
| Description | Sphingosine-1-phosphate (S1P) is a bioactive lipid that exhibits a broad spectrum of biological activities including cell proliferation, survival, migration, cytoskeletal organization, and morphogenesis. It exerts its activity by binding to five distinct G protein-coupled receptors, S1P1/EDG-1, S1P2/EDG-5, S1P3/EDG-3, S1P4/EDG-6, and S1P5/EDG-8. JTE-013 is a potent, selective sphingosine-1-phosphate 2 (S1P2) receptor antagonist that binds to the human and rat receptors with IC50 values of 17 and 22 nM, respectively, (IC50 values >10 μM for human S1P1 and S1P3). It reverses the inhibitory effects of S1P on cell migration of vascular endothelial cells and smooth muscle cells. Similarly, JTE-013 reverses the inhibition of S1P on invasion and migration of B16 melanoma cells. JTE-013 inhibits S1P-induced contraction of, as well as cyclic AMP accumulation in, coronary artery smooth muscle cells. | | Uses | JTE-013 has been used in in vitro blood?brain barrier (BBB) and blood?tumor barrier (BTB) assays. | | Definition | ChEBI: 1-(2,6-dichloro-4-pyridinyl)-3-[(1,3-dimethyl-4-propan-2-yl-6-pyrazolo[3,4-b]pyridinyl)amino]urea is a pyrazolopyridine. | | Biochem/physiol Actions | JTE-013 can enhance the excitability of small-diameter sensory neurons. It has the ability to repress sphingosine 1-phosphate (S1P)-mediated cellular migration. | | storage | Store at +4°C | | References | [1] MELISSA R PITMAN. The sphingosine 1-phosphate receptor 2/4 antagonist JTE-013 elicits off-target effects on sphingolipid metabolism.[J]. Scientific Reports, 2022: 454. DOI: 10.1038/s41598-021-04009-w
[2] MAKOTO OSADA. Enhancement of sphingosine 1-phosphate-induced migration of vascular endothelial cells and smooth muscle cells by an EDG-5 antagonist[J]. Biochemical and biophysical research communications, 2002, 299 3: Pages 483-487. DOI: 10.1016/s0006-291x(02)02671-2
[3] KAYO ARIKAWA. Ligand-dependent inhibition of B16 melanoma cell migration and invasion via endogenous S1P2 G protein-coupled receptor. Requirement of inhibition of cellular RAC activity.[J]. The Journal of Biological Chemistry, 2003, 278 35: 32841-32851. DOI: 10.1074/jbc.m305024200
[4] QIUMIN XU BMED . JTE-013 Alleviates Inflammatory Injury and Endothelial Dysfunction Induced by Sepsis In Vivo and In Vitro[J]. Journal of Surgical Research, 2021, 265: Pages 323-332. DOI: 10.1016/j.jss.2021.03.006
[5] MENGDIE WANG. Inhibition of sphingosine 1-phosphate (S1P) receptor 1/2/3 ameliorates biological dysfunction in rheumatoid arthritis fibroblast-like synoviocyte MH7A cells through Gαi/Gαs rebalancing[J]. Clinical and Experimental Pharmacology and Physiology, 2021, 48 8: 1080-1089. DOI: 10.1111/1440-1681.13460
[6] STEPHANIE S DUSABAN. Sphingosine 1-phosphate receptor 3 and RhoA signaling mediate inflammatory gene expression in astrocytes.[J]. Journal of Neuroinflammation, 2017: 111. DOI: 10.1186/s12974-017-0882-x
[7] NADINE AL ALAM Sawsan I K. FTY720P inhibits hepatic Na(+)-K(+) ATPase via S1PR2 and PGE2.[J]. Biochemistry and Cell Biology, 2016, 94 4: 371-377. DOI: 10.1139/bcb-2016-0025 |
| | JTE-013 Preparation Products And Raw materials |
|